The global situation of MDR-TB. (Q35131998)

6 August 2017

1 reference

title

The global situation of MDR-TB. (English)

1 reference

6 August 2017

Marcos A Espinal

1

1 reference

6 August 2017

publication date

1 January 2003

1 reference

6 August 2017

1 reference

6 August 2017

volume

83

1 reference

6 August 2017

issue

1-3

1 reference

6 August 2017

page(s)

44-51

1 reference

The neglected global tuberculosis problem: a report of the 1992 World Congress on Tuberculosis.

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900058-6

7 January 2021

Streptomycin resistance in pulmonary tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900058-6

7 January 2021

Primary drug resistance in pulmonary tuberculosis in Great Britain: Second national survey, 1963

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900058-6

7 January 2021

Primary drug resistance in Australia in 1968

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900058-6

7 January 2021

Primary drug resistance to the major anti-tuberculosis drugs in Japan. An investigation by the Tuberculosis Research Committee (Ryoken), Japan

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900058-6

7 January 2021

Trends in the prevalence of primary drug resistance in pulmonary tuberculosis in France from 1962 to 1970: a national survey

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900058-6

7 January 2021

Tuberculosis in Kenya: a national sampling survey of drug resistance and other factors

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900058-6

7 January 2021

ANTIBACTERIAL ACTIVITY OF RIFAMYCINS

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900058-6

7 January 2021

Drug-resistant tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900058-6

7 January 2021

Evolution of WHO policies for tuberculosis control, 1948-2001.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900058-6

7 January 2021

Drug-resistant tuberculosis: review of the worldwide situation and the WHO/IUATLD Global Surveillance Project. International Union Against Tuberculosis and Lung Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900058-6

7 January 2021

An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900058-6

7 January 2021

An outbreak of tuberculosis caused by multiple-drug-resistant tubercle bacilli among patients with HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900058-6

7 January 2021

Global surveillance for antituberculosis-drug resistance, 1994-1997. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900058-6

7 January 2021

Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900058-6

7 January 2021

Erasing the World's Slow Stain: Strategies to Beat Multidrug-Resistant Tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900058-6

7 January 2021

Antibiotic resistant tuberculosis in the United Kingdom: 1993-1999.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900058-6

7 January 2021

Worldwide Incidence of Multidrug‐Resistant Tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900058-6

7 January 2021

Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900058-6

7 January 2021

Molecular epidemiology of tuberculosis and other mycobacterial infections: main methodologies and achievements

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900058-6

7 January 2021

Global dissemination of the Mycobacterium tuberculosis W-Beijing family strains

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900058-6

7 January 2021

Worldwide occurrence of Beijing/W strains of Mycobacterium tuberculosis: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900058-6

7 January 2021

Molecular epidemiology of tuberculosis in the Netherlands: a nationwide study from 1993 through 1997.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900058-6

7 January 2021

Clinical consequences and transmissibility of drug-resistant tuberculosis in southern Mexico

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900058-6

7 January 2021

Tuberculosis control and molecular epidemiology in a South African gold-mining community

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900058-6

7 January 2021

Spread of drug-resistant pulmonary tuberculosis in Estonia

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900058-6

7 January 2021

Origin and interstate spread of a New York City multidrug-resistant Mycobacterium tuberculosis clone family

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900058-6

7 January 2021

Mycobacterium tuberculosis Beijing genotype emerging in Vietnam

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900058-6

7 January 2021

Will tuberculosis become resistant to all antibiotics?

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900058-6

7 January 2021

Understanding, predicting and controlling the emergence of drug-resistant tuberculosis: a theoretical framework

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900058-6

7 January 2021

Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900058-6

7 January 2021

10.1016/S1472-9792(02)00058-6

Identifiers

DOI

1 reference

6 August 2017

1 reference